
A study from 2019 to 2021 explored the potential of galectin-3 (Gal-3) as a predictive marker for cardiogenic shock patients on venoarterial extracorporeal membrane oxygenation (VA-ECMO). Of the 73 patients enrolled, 52.05% succumbed in hospital. Key findings indicated that survivors exhibited lower APACHE II scores, higher left ventricular ejection fraction, reduced Gal-3 and BNP levels at 24 and 72 hours, and elevated platelet counts compared to nonsurvivors. Multivariable analysis identified APACHE II score, BNP-T72, and Gal-3-T72 as independent mortality risk factors. Combining these factors yielded a highly effective prediction model with an AUC of 0.884.
Like
Save
Share